Perspective Therapeutics sets date for second-quarter 2026 financial results and business update
The radiopharmaceutical developer said it will release second-quarter 2026 results on Aug. 10 after the market closes and post the announcement in the newsroom section of its website.
Perspective Therapeutics Inc. said it will report second-quarter 2026 financial results and provide a business update on Monday, Aug. 10, 2026, after the market closes. The announcement will be posted in the newsroom section of the company's website. Perspective, which trades on NYSE American under the symbol CATX, describes itself as a radiopharmaceutical development company focused on cancer treatments across the body. The company said its proprietary platform uses the alpha-generating isotope 212Pb to deliver radiation to cancer cells through specialized targeting moieties, while complementary imaging techniques use the same targeting approach to support a theranostic strategy aimed at personalizing treatment and improving outcomes. The company said its U.S. clinical-stage portfolio includes VMT-α-NET for neuroendocrine tumors, VMT01 for melanoma and PSV359 for solid tumors. It is also expanding its regional finished drug product candidate supply network through its proprietary 224Ra/212Pb generator platform to support delivery of patient-ready product candidates for clinical trials and, if approved, commercial operations.
- radiopharmaceutical: A drug that contains radioactive material and is designed to diagnose or treat disease, often by targeting specific cells.
- theranostic: An approach that combines diagnostic imaging and targeted treatment using related or paired agents to help tailor care.
- clinical-stage programs: Drug candidates that are being tested in human studies to evaluate safety and effectiveness.